Practice Guideline Recommendations: Disease-modifying Therapies for Adults with Multiple Sclerosis
Guideline, April 2018
Read Published ArticleThis article presents the recommendations and suggestions for future research of an American Academy of Neurology (AAN) practice guideline on the efficacy and safety of disease-modifying therapies (DMTs) in multiple sclerosis (MS).
Reaffirmed on September 18, 2021.
Recommendations from current practice guideline. Companion to "Systematic Review: Disease-modifying Therapies for Adults with Multiple Sclerosis" (April 2018).
Endorsed by the Consortium of Multiple Sclerosis Centers, the Multiple Sclerosis Association of America, and the National Multiple Sclerosis Society.
Clinician Tools and Materials
Clinician Summary
Download a PDF summary of this guideline product
Companion Publication - Commentary
Download a companion piece to this guideline productCompanion Publication - Identifying Priority Outcomes
Download a companion piece to this guideline productCompanion Publication - Complexity of MS Management
Download a companion piece to this guideline productFull-length Version
Download a PDF of the full guideline product, including full details of the methodology and data analysis
Educational Materials
Other resources related to this guideline
Patient Tools and Materials
Patient Summary - Starting DMTs for MS
Read a summary of the key messages of this guideline product for patients and care partners.Patient Summary - Switching DMTs for MS
Read a summary of the key messages of this guideline product for patients and care partners.Patient Summary - Stopping DMTs for MS
Read a summary of the key messages of this guideline product for patients and care partners.Press Release
Download the AAN press release about this guideline product
Video for Patients
Patient Summary Translation
Translated in Spanish (Español)
Patient Summary Translation
Translated in Spanish (Español)
Patient Summary Translation
Translated in Spanish (Español)